Apogee Therapeutics completes strategic acquisition: deal analysis and pipeline implications. Thursday, September 3, 2026 Apogee Therapeutics has finalized a major strategic acquisition, marking a pivotal expansion of its clinical pipeline. This latest transaction underscores the biotech sector's aggressive push toward targeted therapies and high-impact asset consolidation. Dive into its comprehensive analysis to uncover the deal's structural nuances and long-term market implications. Apogee Therapeutics' disclosure of a completed acquisition under Item 2.01 of Form 8-K marks a deliberate step in consolidating its footprint across the competitive immunology and inflammation (I&I) landscape. In a biotechnology market where capital discipline increasingly dictates deal activity, development-stage companies must continuously balance internal pipeline progression with opportunistic business development. For Apogee, which went public with a mandate to engineer best-in-class, extended-half-life biologics for large-market inflammatory indications, this transaction reinforces its broader clinical strategy and underscores management's willingness to deploy capital to secure intellectual property, platform enhancements, or complementary therapeutic candidates. Transaction architecture and valuation context. Filing under Item 2.01 confirms the formal consummation of the transaction, signaling that all regulatory clearances, shareholder consents, and closing conditions have been satisfied. While specific financial terms in early-stage biotech asset transfers frequently incorporate structured milestone mechanisms, the transaction architecture reflects prevailing biopharma M&A norms: * Risk-Mitigated Deal Structures: Clinical-stage business development routinely utilizes an upfront consideration - typically a blend of cash and equity - paired with contingent value rights (CVRs) or development, regulatory, and commercial milestone payments. This structure protects the acquirer's balance sheet while preserving upside for the selling entity. * Capital Allocation Strategy: Apogee has maintained a strong liquidity profile following its successful 2023 initial public offering and subsequent follow-on financings. Deploying resources toward targeted acquisitions allows the company to accelerate pipeline expansion without diluting its operational runway or derailing core Phase 1 and Phase 2 timelines for lead assets like APG777 and APG808. * Valuation Dynamics: Given the valuation corrections across small- and mid-cap biotechnology over the past 24 months, valuations for early-stage platform technologies and pre-clinical assets have reset to attractive multiples. Apogee's execution at this juncture captures favorable pricing dynamics before upcoming sector-wide clinical catalysts potentially recalibrate asset values. Strategic rationale: deepening the I&I moat. The core thesis supporting Apogee's market valuation is its focus on optimized monoclonal antibodies engineered for significantly extended half-lives. Current standard-of-care agents for atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD) - most notably Sanofi and Regeneron's Dupixent (dupilumab) - require dosing regimens every two to four weeks. Apogee aims to deliver comparable or superior target inhibition with maintenance dosing intervals extended to once every two to three months, or even semi-annually. Within this framework, the completed acquisition provides several critical strategic advantages: * Platform Synergy and Engineering Capabilities: Acquiring complementary technology or early-stage pipeline assets allows Apogee to expand its proprietary antibody engineering platform, optimizing pharmacokinetic (PK) and pharmacodynamic (PD) properties across new targets. * Target Diversification Beyond Core Th2 Pathways: While Apogee's primary focus has centered on IL-13 (APG777), IL-4Rα (APG808), and OX40L (APG990), expanding the portfolio mitigates binary clinical risk. Adding novel mechanistic approaches ensures the company remains relevant as the treatment paradigm evolves toward combination therapies and broad-spectrum pathway modulation. * Intellectual Property Hardening: Consolidating intellectual property around specific antibody modifications and formulation technologies creates a more formidable defensive barrier against both legacy pharmaceutical incumbents and emergent fast-followers. Market implications and competitive positioning. The global market for immunology and inflammation therapeutics exceeds $100 billion annually, with biologics representing the fastest-growing segment. However, competition among next-generation developers is intensifying. Established players such as Eli Lilly (with lebrikizumab), AbbVie, and Amgen are aggressively defending their franchises, while mid-cap biotechs like Upstream Bio and Tourmaline Bio are advancing competing long-acting modalities. By formalizing this transaction, Apogee achieves several competitive outcomes: * Strengthened Partnering Appeal: As mega-cap pharmaceutical companies face patent cliffs on blockbusters later this decade, de-risked and differentiated immunology pipelines represent prime licensing or buyout targets. A broader, well-protected portfolio enhances Apogee's standing as an attractive strategic partner or potential acquisition target itself. * Operational Scale: Moving beyond a single-asset narrative is essential for public market durability. The expansion of Apogee's developmental portfolio distributes clinical development risk across multiple discrete milestones, smoothing out binary event volatility for institutional shareholders. * Differentiation in Atopic Dermatitis and Respiratory Diseases: By acquiring assets that complement its long-acting strategy, Apogee can more credibly contest market share against both standard-of-care injectables and emerging oral small molecules (such as JAK inhibitors), which remain constrained by class-wide safety warnings. Strategic outlook. The integration of the acquired assets into Apogee's broader research and development engine will now hinge on execution. The primary metrics of success over the next 12 to 24 months will be the seamless initiation of clinical-enabling studies, the preservation of the company's cash runway into key data readouts, and the empirical validation of the extended-dosing hypothesis in human trials. If Apogee can leverage this acquisition to replicate the pharmacokinetics of its lead programs across additional targets, it will firmly establish itself as a premier innovator in the modern immunology sector. Ready to analyze your next deal? Upload your CIM for instant AI-powered analysis - financial extraction, risk assessment, and valuation in minutes. Analyze your own CIM. Upload a CIM and get financials, risks, and valuation in seconds.

'Who knows what they're taking?': people risk the gray market for the newest weight-loss drug. Retatrutide, not yet approved by the FDA, is the latest wonder drug to shed pounds despite warnings from doctors About two years ago, Henry, who is 6ft 3in, weighed 210lb, which meant he was only slightly overweight, according to the Centers for Disease Control and Prevention body mass index. Still, the thirtysomething who lives in the Pacific north-west had hypertension, sleep apnea and body image issues, so he started taking the weight-loss drug Ozempic. While he dropped pounds, he experienced constipation, a common side-effect, so he wanted to try retatrutide, another peptide which not only targets GLP-1 but two other hormone receptors as well. He had read about it in the news and on Reddit forums. The problem is, the US Food and Drug Administration has not approved the drug, so Henry bought it online from sellers in China. Henry, who did not want his last name used, is among a growing number of people dissatisfied with the revolutionary weight-loss drugs that can be obtained legally with a prescription and have instead turned to the gray market to purchase retatrutide, which is manufactured by the pharmaceutical company Eli Lilly and is being studied in clinical trials. Physicians see the drug as a promising potential solution for people struggling with obesity, but strongly warn patients that they are seriously risking their health by using it without oversight from doctors and government regulators. Yet these warnings often go unheeded. "All of these medications should be monitored and prescribed in a medical situation where the doctor or the clinic is partnering with the patient on a complete plan" including "monitoring their lab [work], their vital signs, their response", said Dr David Shafer, a plastic surgeon in New York who takes the drug. "It's really the self-prescribing and unknown usage that is leading to a lot of the problems." Retatrutide could work well in helping people lose weight - and potentially have other health benefits - because whereas Ozempic targets one receptor, and tirzepatide, sold as Mounjaro and Zepbound, targets GLP-1 and the receptor GIP, the newer drug is a "triple agonist", meaning it targets those two receptors and glucagon, which speeds up the body's metabolism and helps it break down fat cells for energy. In an 80-week clinical trial, patients with severe obesity and heart disease taking the highest weekly doses of retatrutide achieved an average weight loss of 22%, or 55lb, according to Eli Lilly. "The more natural gut hormones that you upregulate, the more weight loss we see," said Dr Caroline Messer, an endocrinologist in New York. If a patient were to ask Messer whether she recommends the drug, she would say: "Wholeheartedly - but not through the gray market. Just wait till it hits the market." Patients, in fact, ask Messer about retatrutide about five times daily, she said. Most of them "have maxed out on Zepbound and still are not at their target weight, but it's also people who enjoy being at the cutting edge of things", she said. A Reddit group dedicated to the drug gets more than 179,000 visits each week. The demand for the drug is "concerning because of the way it's been popularized through podcasts and politicians, not through doctor-patient relationships", said Dan Burke, a former division chief of the US Food and Drug Administration office of criminal investigations. In August, Eli Lilly announced it would provide a limited number of patients access to the drug before the FDA approves it, Reuters reported. But Messer said that while the process is supposed to help patients "who are desperate" to try the drug, it is "just so unbelievably difficult" to qualify for special access that it could take years to obtain it, by which time the FDA will likely have already approved it. "It pits the patient against the doctor because now the patient thinks that we are not doing everything we can to get them the medication, where it's really actually just this super-onerous process," Messer said. As such, patients are finding other ways to obtain the drug. The Reddit group features a "beginner's guide" to getting it through the gray market and encourages people to "find communities (not on Reddit)", "get tapped in" and "vet vet vet like your money depends on it". The guide also provides instructions on dosing and warns people not to use the product if it comes in a prefilled pen. Eli Lilly recently filed lawsuits against six companies that allegedly sold the drug, including Lone Star Peptide, which is based in Texas and markets the drug for "research use only", and Aesthetic Envy Cosmetic Centers, a med-spa in Sacramento, California. A person who answered the phone at Lone Star Peptide declined to comment. Aesthetic Envy did not respond to a request. "Illegal drugs made outside of a regulated, inspected supply chain are more likely to contain bacteria and other harmful contaminants and impurities. Consumers have no way to know whether these products are safe or effective," a lawsuit states. Messer argues that obtaining the drug through the gray market is potentially dangerous because patients do not know how much of the drug the product contains or its purity. In June, the Victoria state government in Australia reported six cases of acute liver toxicity among patients who consumed a product labeled as retatrutide. "This is something that you are injecting, and you don't know where it's being made," Messer said. Despite warnings from physicians and government agencies, patients are still buying the drug on the gray market - and at least sometimes getting their desired results. "The ones who have plateaued on tirzepatide [Zepbound] are starting to lose weight again, so losing an additional 20 to 30lb," Messer said. Henry has not told his doctor he is taking retatrutide because he did not want documentation of it, he said. But he has lost 30lb since starting on it and is "doing good", even though his skin has become extra sensitive, a common side-effect of the drug. "For the first time in my entire life, I feel like I am in control of my body," said Henry, who also now drinks less alcohol. Shafer, the plastic surgeon, said that even if people are not obtaining retatrutide from a prescription, they should disclose their use of it to their provider. "The doctors are not the police, and they are not going to turn you in for buying something online," Shafer said. "The doctor and the patient can partner together to formulate the best plan." Shafer said he started taking a GLP-1 agonist because he wanted to lose about 20lb for health and aesthetic reasons. He then started taking retatrutide because his weight loss had plateaued, and also because he expected to someday prescribe it to patients and wanted to see how it worked. He obtained it from a compounding pharmacy, which prepares medications on site. He said it not only helped him lose weight but improved his muscle tone and reduced his blood pressure, which had been slightly elevated. Shafer argues that the FDA should expedite its review of it. "I don't think it's something that should take 10 years for them to do studies on," Shafer said. "Then you're going to have all these other people that are doing it anyway off the black market, and who knows what it is they are taking."

Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases. Aug 31, 2026, 06:45 ET Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function Initial Phase 1 data show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile Acquisition strengthens Lilly's immunology capabilities and its opportunity to elevate the standard of care for immune-mediated conditions with high unmet need INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026 /PRNewswire/ - Eli Lilly and Company (NYSE: LLY) and Merida Biosciences, Inc. (Merida), a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, today announced a definitive agreement for Lilly to acquire Merida. Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions. The precision degradation approach is intended to address the biological cause of these diseases, rather than broadly suppressing the immune system, as many current therapies do. Merida's lead program, MER511, is in Phase 1 development for Graves' disease and thyroid eye disease (TED), conditions driven by thyroid-stimulating immunoglobulins, which are autoantibodies that activate the thyroid-stimulating hormone receptor. Graves' disease affects approximately 3 million people in the U.S., and patients face elevated cardiovascular risk and mortality. Roughly 25 to 40 percent of people with Graves' disease go on to develop TED, which can cause pain, disfigurement, and in severe cases, vision loss. While there are approved treatments for both conditions, none directly target the autoantibodies that cause them. Because pathogenic autoantibodies drive a wide range of serious diseases, Merida's platform has potential application well beyond its lead program. The company's pipeline also includes MER769, a preclinical program focused on food allergy, asthma, chronic spontaneous urticaria and other diseases driven by the antibody responsible for triggering allergic reactions, along with earlier-stage programs in kidney diseases such as membranous nephropathy and other immune-mediated conditions. "We're building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects. Merida's lead program is designed to do exactly that: selectively and directly eliminating the autoantibodies causing Graves' disease and thyroid eye disease, while preserving normal immune function, with initial Phase 1 data already pointing to the potential for improved efficacy and safety," said Francisco Ramírez-Valle, M.D., Ph.D., senior vice president, Lilly immunology research and early clinical development. "We see potential to apply this precision approach across a broad range of antibody-driven diseases, and we look forward to advancing this novel technology working with the Merida team." "Merida was founded to fundamentally change how autoimmune and allergic diseases are treated, by targeting the antibodies driving them directly, rather than suppressing the immune system broadly. Under our CSO and founder Dario Gutierrez's scientific leadership, our team has advanced that idea from concept to clinical data, and what we've seen so far reinforces our conviction that this approach can make a meaningful difference for patients," said Adam Townsend, chief executive officer of Merida. "Today's announcement reflects the hard work of the entire Merida team, and joining Lilly gives our science the resources and commitment to realize its potential for patients with immune-mediated conditions." Under the terms of the agreement, Lilly will acquire Merida and pay up to $2.875 billion in cash, inclusive of an upfront payment, and contingent milestone payments. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance. Ropes & Gray LLP is acting as legal counsel to Lilly. Centerview Partners LLC is acting as an exclusive financial advisor, and Goodwin Procter LLP is acting as legal counsel to Merida. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY About Merida Biosciences Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers. This approach, enabled by advances in protein engineering and immunology, has the potential to address numerous autoimmune and allergic conditions that are inadequately treated today. Please visit www.meridabio.com to learn more. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of Merida and Merida's product candidates for immune-mediated diseases, and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in closing and implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will close the transaction or realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this release, or that the acquisition will yield commercially successful products. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. | Refer to: | Megan Talon, [email protected] (Media) | | / | Michael Czapar, [email protected] (Investors) | | / | Cynthia Clayton, [email protected] (Merida Media) | SOURCE Eli Lilly and Company